Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Aims: To test the hypothesis that Diastolic dysfunction severity correlates with adverse clinical outcome in patients with systolic heart failure.
Recent studies have explored the prognostic role of TDI-derived parameters in major cardiac diseases, such as heart failure, acute myocardial infarction, and hypertension.(1-3). In these conditions, myocardial mitral annular or basal segmental (Sm) systolic and early diastolic (Ea or Em) velocities have been shown to predict mortality or cardiovascular events. In particular, those with reduced Sm or Em values of <3 cm/s have a very poor prognosis. In heart failure and after myocardial infarction, noninvasive assessment of LV diastolic pressure by transmitral to mitral annular early diastolic velocity ratio (E/Ea or E/Em) is a strong prognosticator, especially when E/Ea is > or =15. (3) Conventional Doppler indices and TDI parameters correlated with functional class in patients with advanced heart failure. The E/E' ratio, which probably reflects high LV end-diastolic pressure, was the best measure for differentiating patients with functional class III and IV, and it also correlated with cardiac mortality and hospitalization for worsening heart failure, thereby providing additional value to standard echocardiographic measures(4-5) In our study we'll try to demonstrate that clinical deterioration of patients with LV systolic dysfunction directly correlates with parameters of their diastolic function and that these parameters more predictable than changes in LVEF.
This study will be performed on the base of Natania Heart Institute (out of hospital clinic).
Within community-based population study we'll select the patients with LV systolic dysfunction.
The participants will be classified according to their LV systolic function, functional class (NYHA) of HF.
Approximately 200 subjects will be enrolled.
The participants will be evaluate according their baseline features, clinical status using EQ-5D score, KCCQ Overall Summary Score, KCCQ Symptom Frequency Score.
After enrolment all our patients will undergo:
Follow-up Follow-up at least 2 years With out patients clinical evaluation monthly Exercise capacity evaluation every 3 mo Echocardiography one in half a year
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| -Time to death from any cause or fist hospital admission for worsening HF, whichever occurs fist. | Follow-up -2 y With out patients clinical evaluation monthly Exercise capacity evaluation every 3 mo Echocardiography one in half a year | 2 y |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline to month 6 : in KCCQ Overall Summary Score | Change from baseline to month 6 : in KCCQ Overall Summary Score in KCCQ Symptom Frequency Score. of EQ-5D in NYHA class of each time- point. in maximal work capacity in 6-min walk test Change in VO2 Total number of hospital admission for worsening HF Total duration of hospital admission for worsening HF Total number of hospital admission for non-fatal c-v event, resuscitated sudden death, arrhythmia, new onset atrial fibrillation. |
Not provided
Summary of Subject Eligibility criteria:
Not provided
Not provided
Not provided
Study population
This study will be performed on the base of Natania Heart Institute (out of hospital clinic).
Within community-based population study we'll select the patients with LV systolic dysfunction.
The participants will be classified according to their LV systolic function, functional class (NYHA) of HF.
Approximately 200 subjects will be enrolled.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Korotinsky Svetlana, doctor | Contact | 03-6313870 | sv_korot@walla.co.il |
| Name | Affiliation | Role |
|---|---|---|
| Korotinsky Svetlana, doctor | Israel: Clalit Health Services | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 mo |